万古霉素治疗革兰阳性球菌感染重症肺炎的临床效果(1)
[摘要]目的 研究万古霉素治疗革兰阳性球菌感染重症肺炎的临床效果。方法 选取2016年4月～2019年3月我院收治的80例革兰阳性球菌感染的重症肺炎患者作为研究对象，按照随机数字表法分为对照组和观察组，每组各40例。对照组采用左氧氟沙星治疗，观察组采用万古霉素治疗，比较两组患者的治疗效果、细菌清除率、治疗后产生的不良反应情况。结果 观察组患者的治疗总有效率为95.00%，高于对照组的75.00%，差异有统计学意义(P<0.05);观观察组患者的细菌总清除率为95.00%，高于对照组的75.00%，差异有统计学意义(P<0.05);观察组患者的不良反应总发生率为5.00%，低于对照组的22.50%，差异有统计学意义(P<0.05)。结论 万古霉素治疗革兰阳性球菌感染的重症肺炎的效果显著，安全有效，不良反应少。
[关键词]万古霉素;革兰阳性球菌;重症肺炎;疗效;机制;肺部感染
[中图分类号] R563.1 [文献标识码] A [文章编号] 1674-4721(2020)3(a)-0185-03
Clinical effect of Vancomycin in the treatment of severe pneumonia infected by Gram-positive cocci
LI Jing DING Jin-feng XIAO Wen-xiang
Department of Pharmacy， CITIC Huizhou Hospital， CITIC Huizhou Hospital Co.， Ltd.， Guangdong Province， Huizhou 516001， China
[Abstract] Objective To study the clinical effect of Vancomycin in the treatment of severe pneumonia infected by Gram-positive cocci. Methods Eighty patients with severe pneumonia infected by Gram-positive cocci treated in our hospital from April 2016 to March 2019 were selected as the study subjects. The patients were divided into the control group and the observation group according to the random number table method， with 40 cases in each group. Patients in the control group were treated with Levofloxacin， and in the observation group， patients were treated with Vancomycin. The therapeutic effects， bacterial clearance rate， and adverse reactions in two groups after treatment were compared. Results The total effective rate of the observation group was 95.00%， which was higher than that of the control group accounting for 75.00%， and the difference was statistically significant (P<0.05). The total bacterial clearance rate of the observation group was 95.00%， which was higher than that of the control group accounting for 75.00%， with statistical significance (P<0.05). The total incidence of adverse reactions in the observation group was 5.00%， which was lower than that in the control group accounting for 22.5%， with statistical significance (P<0.05). Conclusion Vancomycin is effective in the treatment of severe pneumonia caused by gram-positive cocci. It is safe and effective， which has less adverse reactions.
[Key words] Vancomycin; Gram-positive cocci; Severe pneumonia; Efficacy; Mechanism; Lung infection
重癥肺炎是导致重症病变住院患者死亡的重要原因。而革兰阳性球菌是重症肺炎重要的病原体，常见的病原体包括金黄色葡萄球菌、肺炎链球菌等。抗生素治疗是重症肺炎最重要的治疗方式，能够抑制或杀灭致病病原体。但近年来，由于抗生素的不规范应用等原因，常用抗生素对重症肺炎的疗效欠佳。万古霉素属于三环糖肽类抗生素，通过感染病原体细胞壁合成而抑制病原体的生长和增殖，对金黄色葡萄球菌、链球菌及部分杆菌具有良好的作用，细菌耐药性较低。因此，万古霉素在严重感染患者的治疗中广泛应用。以往研究显示，在耐甲氧西林金黄色葡萄球菌感染所致重症肺炎的治疗中，万古霉素具有举足轻重的作用，该药对革兰阳性球菌具有非常强大的杀菌作用，是治疗革兰阳性球菌的最后一道防线，还可以治疗败血症、皮肤软组织感染等疾病[1]。本研究选取我院收治的80例革兰阳性球菌感染的重症肺炎患者作为研究对象，旨在探讨万古霉素治疗革兰阳性球菌感染的重症肺炎的临床效果，现报道如下。, http://www.100md.com(李静 丁金峰 肖文香)
[关键词]万古霉素;革兰阳性球菌;重症肺炎;疗效;机制;肺部感染
[中图分类号] R563.1 [文献标识码] A [文章编号] 1674-4721(2020)3(a)-0185-03
Clinical effect of Vancomycin in the treatment of severe pneumonia infected by Gram-positive cocci
LI Jing DING Jin-feng XIAO Wen-xiang
Department of Pharmacy， CITIC Huizhou Hospital， CITIC Huizhou Hospital Co.， Ltd.， Guangdong Province， Huizhou 516001， China
[Abstract] Objective To study the clinical effect of Vancomycin in the treatment of severe pneumonia infected by Gram-positive cocci. Methods Eighty patients with severe pneumonia infected by Gram-positive cocci treated in our hospital from April 2016 to March 2019 were selected as the study subjects. The patients were divided into the control group and the observation group according to the random number table method， with 40 cases in each group. Patients in the control group were treated with Levofloxacin， and in the observation group， patients were treated with Vancomycin. The therapeutic effects， bacterial clearance rate， and adverse reactions in two groups after treatment were compared. Results The total effective rate of the observation group was 95.00%， which was higher than that of the control group accounting for 75.00%， and the difference was statistically significant (P<0.05). The total bacterial clearance rate of the observation group was 95.00%， which was higher than that of the control group accounting for 75.00%， with statistical significance (P<0.05). The total incidence of adverse reactions in the observation group was 5.00%， which was lower than that in the control group accounting for 22.5%， with statistical significance (P<0.05). Conclusion Vancomycin is effective in the treatment of severe pneumonia caused by gram-positive cocci. It is safe and effective， which has less adverse reactions.
[Key words] Vancomycin; Gram-positive cocci; Severe pneumonia; Efficacy; Mechanism; Lung infection
重癥肺炎是导致重症病变住院患者死亡的重要原因。而革兰阳性球菌是重症肺炎重要的病原体，常见的病原体包括金黄色葡萄球菌、肺炎链球菌等。抗生素治疗是重症肺炎最重要的治疗方式，能够抑制或杀灭致病病原体。但近年来，由于抗生素的不规范应用等原因，常用抗生素对重症肺炎的疗效欠佳。万古霉素属于三环糖肽类抗生素，通过感染病原体细胞壁合成而抑制病原体的生长和增殖，对金黄色葡萄球菌、链球菌及部分杆菌具有良好的作用，细菌耐药性较低。因此，万古霉素在严重感染患者的治疗中广泛应用。以往研究显示，在耐甲氧西林金黄色葡萄球菌感染所致重症肺炎的治疗中，万古霉素具有举足轻重的作用，该药对革兰阳性球菌具有非常强大的杀菌作用，是治疗革兰阳性球菌的最后一道防线，还可以治疗败血症、皮肤软组织感染等疾病[1]。本研究选取我院收治的80例革兰阳性球菌感染的重症肺炎患者作为研究对象，旨在探讨万古霉素治疗革兰阳性球菌感染的重症肺炎的临床效果，现报道如下。, http://www.100md.com(李静 丁金峰 肖文香)
参见：首页 > 医疗版 > 疾病专题 > 呼吸内科 > 肺炎